In earlier clinical trials, targeting CD47 resulted in common side effects of anemia, thrombocytopenia, lymphopenia and hyperbilirubinemia.93 One anti-CD47 mAb, magrolimab (humanized IgG4 mAb), has made it through to phase 3 trials in patients with myelodysplastic syndrome (ENHANCE/NCT04313881), but anti-CD47 mAbs have not yet had such success in melanoma. Here, CD47 is linked to Hyperbilirubinemia.